Improved anti-hepatocellular carcinoma effect by enhanced Co-delivery of Tim-3 siRNA and sorafenib via multiple pH triggered drug-eluting nanoparticles

Effective systemic treatment for hepatocellular carcinoma (HCC) remains urgently needed. Sorafenib is the first FDA-approved systemic treatment for HCC. However, individual HCC patents’ response to sorafenib varies greatly. How to enhance the anti-HCC effect of sorafenib is still a significant chall...

Descripción completa

Detalles Bibliográficos
Autores principales: Song, Chenghua, Zhang, Jia, Wen, Ruichao, Li, Qingshan, Zhou, Jiaxuan, Xiaoli liu, Wu, Zheng, Lv, Yi, Wu, Rongqian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Full Length Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9287642/
https://www.ncbi.nlm.nih.gov/pubmed/35856043
http://dx.doi.org/10.1016/j.mtbio.2022.100350

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9287642/
https://www.ncbi.nlm.nih.gov/pubmed/35856043
http://dx.doi.org/10.1016/j.mtbio.2022.100350

Ejemplares similares